Search

Your search keyword '"SLN, solid lipid nanoparticle"' showing total 6 results
Start Over Descriptor "SLN, solid lipid nanoparticle"
6 results on '"SLN, solid lipid nanoparticle"'

1. The influence of the gut microbiota on the bioavailability of oral drugs

Author

Ying Han, Xintong Zhang, Wei Huang, Zhonggao Gao, and Mingji Jin

Subjects
SLC, solute carrier, Bioavailability, AMI, amiodarone, MPA, mycophenolic acid, TLCA, taurolithocholate, ASP, amisulpride, RA, rheumatoid arthritis, Review, NRs, nitroreductases, MDR1, multidrug resistance gene 1, NaGC, sodium glycholate, MATEs, multidrug and toxin extrusion proteins, NMEs, new molecular entities, 0302 clinical medicine, HFD, high fat diet, P-gp, P-glycoprotein, ACS, amphipathic chitosan derivative, Medicine, General Pharmacology, Toxicology and Pharmaceutics, LCA, lithocholic acid, 0303 health sciences, Gastrointestinal tract, IBD, inflammatory bowel disease, pKa, dissociation constant, RBC, red blood cell, FA, folate, OATs, organic anion transporters, 030220 oncology & carcinogenesis, MKC, monoketocholic acid, the GI tract, the gastrointestinal tract, AQP4, aquaporin 4, OCTNs, organic zwitterion/cation, T2D, type 2 diabetes, Gut microbiota, RM1-950, WHO, World Health Organization, 03 medical and health sciences, EcN, Escherichia coli Nissle 1917, Drug Transport Process, BDEPT, the bacteria-directed enzyme prodrug therapy, BCS, biopharmaceutics classification system, NEC, necrotizing enterocolitis, DRPs, digoxin reduction products, NaDC, sodium deoxycholate, Probiotics, CPP, cell-penetrating peptide, OCTs, organic cation transporters, TDCA, taurodeoxycholate, cgr operon, cardiac glycoside reductase operon, RA - Rheumatoid arthritis, DCA, deoxycholic acid, AA, ascorbic acid, BBR, berberine, Personalized medicine, BDDCS, the biopharmaceutics drug disposition classification system, SSZ, sulfasalazine, UDC, ursodeoxycholic acid, PPIs, proton pump inhibitors, BCRP, breast cancer resistance protein, CS, chitosan, Gut flora, Bioinformatics, PD, Parkinson's disease, SLN, solid lipid nanoparticle, SGLT-1, sodium-coupled glucose transporter 1, Oral administration, MRP2, multidrug resistance-associated protein 2, FAO, Food and Agriculture Organization of the United Nations, SVCT-1/2, the sodium-dependent vitamin C transporter-1/2, an OTC drug, an over-the-counter drug, CA, cholic acid, biology, ABC, ATP-binding cassette, T1DM, type 1 diabetes mellitus, NSAIDs, non-steroidal anti-inflammatory drugs, AR, azoreductase, GCDC, glycochenodeoxycholate, Drug delivery, GL, glycyrrhizic acid, PT, pectin, LPS, lipopolysaccharide, TME, the tumor microenvironment, T1D, type 1 diabetes, TCDC, taurochenodeoxycholate, Oral drugs, MDR1a, multidrug resistance protein-1a, SCFAs, short-chain fatty acids, CDCA, chenodeoxycholic acid, 030304 developmental biology, business.industry, dhBBR, dihydroberberine, biology.organism_classification, HTC, hematocrit, PWSDs, poorly water-soluble drugs, Colon-specific drug delivery system, stomatognathic diseases, SP, sulfapyridine, 5-ASA, 5-aminosalicylic acid, BSH, bile salt hydrolase, TCA, taurocholate, Therapeutics. Pharmacology, business
Abstract

Due to its safety, convenience, low cost and good compliance, oral administration attracts lots of attention. However, the efficacy of many oral drugs is limited to their unsatisfactory bioavailability in the gastrointestinal tract. One of the critical and most overlooked factors is the symbiotic gut microbiota that can modulate the bioavailability of oral drugs by participating in the biotransformation of oral drugs, influencing the drug transport process and altering some gastrointestinal properties. In this review, we summarized the existing research investigating the possible relationship between the gut microbiota and the bioavailability of oral drugs, which may provide great ideas and useful instructions for the design of novel drug delivery systems or the achievement of personalized medicine., Graphical abstract The gut microbiota may influence the bioavailability of oral drugs by the microbial enzyme activity, affecting the drug transport or changing the gastrointestinal properties. This may provide us some advice on preventing the possible drug–drug interaction and offer us some useful strategies for the drug delivery system design.Image 1

Published
2021

2. Role of nanostructures in improvising oral medicine

Author

Sumit Ghosh, Parames C. Sil, and Shatadal Ghosh

Subjects
BCRP, breast cancer resistance protein, TB, tuberculosis, Health, Toxicology and Mutagenesis, OXA, oxaliplatin, Oral medicine, PNL, PEGylated lipid nanoparticles, 010501 environmental sciences, Toxicology, 01 natural sciences, SLN, solid lipid nanoparticle, 0302 clinical medicine, DM, diabetes mellitus, NP, nanoparticle, Oral route, NSAID, non-steroidal anti-inflammatory drug, Liposome, FRET, Foster resonance energy transfer, IBD, inflammatory bowel disease, LG, Lakshadi Guggul, DDS, drug delivery system, GI, gastrointestinal, Controlled release, MFS, Miltefosine, SMA, styrene maleic acid, AMCNS, cationic niosome-based azithromycin delivery systems, AT1R, angiotensin II receptor type 1, Drug delivery, OA, osteoarthritis, pSiO, porous silica oxide, MSN, mesoporous silica nanoparticle, MNBNC, Micronucleated Binucleated Cells, Materials science, WGA, wheat germ agglutinin, Drug delivery system, PZQ, praziquantel, Nanotechnology, pSi, porous silicon, AD, Alzheimer’s disease, CNL, conventional lipid nanoparticles, Article, EPR, enhanced permeability and retention effect, 03 medical and health sciences, Pharmacokinetics, TPGS, tocopheryl polyethylene glycol succinate, lcsh:RA1190-1270, CSC, core shell corona nanolipoparticles, MTX, methotrexate, DCK, N-deoxycholyl-l-lysyl-methylester, AmB, amphotericin B, PD, Parkinson’s disease, PEG, polyethylene glycol, lcsh:Toxicology. Poisons, 0105 earth and related environmental sciences, LNC, Lipid Nanocapsule, PLGA, polylactic-co-glycolic acid, TNBS, trinitrobenzenesulphonic acid, NPC, nanoparticulate carriers, SMEDD, self microemulsifying drug delivery system, PAMAM, poly (amidoamine), Mesoporous silica, DOX, doxorubicin, Tmf, tamoxifen, Nanostructures, GMO, glyceryl monoolein, Targeted drug delivery, 5-FU, 5-fluorouracil, PIP, 1-piperoylpiperidine, AP, acetylpuerarin, 030217 neurology & neurosurgery, Oral retinoid
Abstract

Highlights • Nanotechnology facilitates oral administration of drugs. • Various nanostructures have been designed for this purpose. • These nanoformulations are useful for many diseases., The most preferable mode of drugs administration is via the oral route but physiological barriers such as pH, enzymatic degradation etc. limit the absolute use of this route. Herein lies the importance of nanotechnology having a wide range of applications in the field of nano-medicine, particularly in drug delivery systems. The exclusive properties particularly small size and high surface area (which can be modified as required), exhibited by these nanoparticlesrender these structures more suitable for the purpose of drug delivery. Various nanostructures, like liposomes, dendrimers, mesoporous silica nanoparticles, etc. have been designed for the said purpose. These nanostructures have several advantages over traditional administration of medicine. Apart from overcoming the pharmacokinetic and pharmacodynamics limitations of many potential therapeutic molecules, they may also be useful for advanced drug delivery purposes like targeted drug delivery, controlled release, enhanced permeability and retention (EPR) effect. In this review, we attempt to describe an up-to-date knowledge on various strategically devised nanostructures to overcome the problems related to oral drug administration.

Published
2019

3. Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome

Author

George Frimpong Boafo, Zhongjian Chen, Marwa Ahmed Sallam, Qingqing Xiao, Makhloufi Zoulikha, and Wei He

Subjects
Small interfering RNA, ARDS, DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane, IFN, interferons, Review, CS, cigarette smoke, TNF-α, tumor necrosis factor-α, MIF, macrophage migration inhibitory factor, AAV, adeno-associated virus, General Pharmacology, Toxicology and Pharmaceutics, AV, adenovirus, dsDNA, double-stranded DNA, DODAP, 1,2-dioleyl-3-dimethylammonium-propane, AM, alveolar macrophage, pDNA, plasmid DNA, PS, pulmonary surfactant, EpiC, epithelial cell, RNAi, RNA interference, Mrna level, HMGB1, high-mobility group box 1, NETs, neutrophil extracellular traps, SNALP, stable nucleic acid lipid particle, VILI, ventilator-induced lung injury, DODMA, 1,2-dioleyloxy-N,N-dimethyl-3-aminopropane, ALI/ARDS, PF, pulmonary fibrosis, HNPs, hybrid nanoparticles, PAMPs, pathogen-associated molecular patterns, DDAB, dimethyldioctadecylammonium bromide, TGF-β, transforming growth factor-β, DAMPs, danger-associated molecular patterns, HALI, hyperoxic acute lung injury, NPs, nanoparticles, PDGFRα, platelet-derived growth factor receptor-α, PEG, polyethylene glycol, PEI, polyethyleneimine, VALI, ventilator-associated lung injury, EC, endothelial cell, CPP, cell-penetrating peptide, ATII, alveolar cell type II, medicine.disease, PMs, polymeric micelles, DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine, PD-L1, programmed death ligand-1, COPD, chronic obstructive pulmonary disease, HMVEC, human primary microvascular endothelial cell, siRNA, small interfering RNA, siRNA, ALI/ARDS, acute lung injury/acute respiratory distress syndrome, EPC, egg phosphatidylcholine, Nanoparticles, LPS, lipopolysaccharides, N/P ratio, nitrogen /phosphate ratio, Chemokine, PRR, pattern recognition receptor, EXOs, exosomes, DOPE, 1,2-dioleoyl-L-α-glycero-3-phosphatidylethanolamine, PEEP, positive end-expiratory pressure, ICAM-1, intercellular adhesion molecule-1, Inflammatory diseases, Hem-CLP, hemorrhagic shock followed by cecal ligation and puncture septic challenge, Bioinformatics, SLN, solid lipid nanoparticle, Cellular uptake, miRNA, microRNA, RISC, RNA-induced silencing complex, NF-κB, nuclear factor kappa B, PLGA, poly(D,L-lactic-co-glycolic acid), biology, FDA, US Food and Drug Administration, Ago-2, argonaute 2, DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, PAMAM, polyamidoamine, Endosomal escape, mRNA, messenger RNA, medicine.anatomical_structure, PAI-1, plasminogen activator inhibitor-1, shRNA, short RNA, DC-Chol, 3β-(N-(N’,N’-dimethylethylenediamine)-carbamoyl) cholesterol, Drug delivery, DOSPA, 2,3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium, TLR, Toll-like receptor, PFC, perfluorocarbon, Acute respiratory distress, Lung injury, DPI, dry powder inhaler, eggPG, L-α-phosphatidylglycerol, ROS, reactive oxygen species, medicine, Pulmonary administration, DOTMA, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium, Lung, business.industry, MEND, multifunctional envelope-type nano device, CFDA, China Food and Drug Administration, ATI, alveolar cell type I, RIP2, receptor-interacting protein 2, Myd88, myeloid differentiation primary response 88, biology.protein, dsRNA, double-stranded RNA, CXCR4, C-X-C motif chemokine receptor type 4, business, DOGS, dioctadecyl amido glycin spermine
Abstract

The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of several unmet medical needs, including acute lung injury/acute respiratory distress syndrome (ALI/ARDS) wherein siRNA may be implemented to modify the expression of pro-inflammatory cytokines and chemokines at the mRNA level. The clear anatomy, accessibility, and relatively low enzyme activity make the lung a good target for local siRNA therapy. However, the clinical translation of siRNA is hampered by the inefficient delivery of siRNA therapeutics to the target cells due to the properties of naked siRNA. Thus, this review will focus on the various delivery systems that can be used and the different barriers that need to be surmounted for the development of stable inhalable siRNA formulations for human use before siRNA therapeutics for ALI/ARDS become available in the clinic., Graphical abstract The pulmonary administration of siRNA in an appropriate delivery vector seems promising to treat undruggable lung diseases such as acute lung injury/acute respiratory distress syndrome ALI/ARDS.Image 1

Published
2021

4. Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome.

Author

Zoulikha M, Xiao Q, Boafo GF, Sallam MA, Chen Z, and He W

Abstract

The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of several unmet medical needs, including acute lung injury/acute respiratory distress syndrome (ALI/ARDS) wherein siRNA may be implemented to modify the expression of pro-inflammatory cytokines and chemokines at the mRNA level. The properties such as clear anatomy, accessibility, and relatively low enzyme activity make the lung a good target for local siRNA therapy. However, the translation of siRNA is restricted by the inefficient delivery of siRNA therapeutics to the target cells due to the properties of naked siRNA. Thus, this review will focus on the various delivery systems that can be used and the different barriers that need to be surmounted for the development of stable inhalable siRNA formulations for human use before siRNA therapeutics for ALI/ARDS become available in the clinic., (© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.)

Published
2022
Full Text
View/download PDF

5. The influence of the gut microbiota on the bioavailability of oral drugs.

Author

Zhang X, Han Y, Huang W, Jin M, and Gao Z

Abstract

Due to its safety, convenience, low cost and good compliance, oral administration attracts lots of attention. However, the efficacy of many oral drugs is limited to their unsatisfactory bioavailability in the gastrointestinal tract. One of the critical and most overlooked factors is the symbiotic gut microbiota that can modulate the bioavailability of oral drugs by participating in the biotransformation of oral drugs, influencing the drug transport process and altering some gastrointestinal properties. In this review, we summarized the existing research investigating the possible relationship between the gut microbiota and the bioavailability of oral drugs, which may provide great ideas and useful instructions for the design of novel drug delivery systems or the achievement of personalized medicine., Competing Interests: The authors have no conflicts of interest to declare., (© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.)

Published
2021
Full Text
View/download PDF

6. Role of nanostructures in improvising oral medicine.

Author

Ghosh S, Ghosh S, and Sil PC

Abstract

The most preferable mode of drugs administration is via the oral route but physiological barriers such as pH, enzymatic degradation etc. limit the absolute use of this route. Herein lies the importance of nanotechnology having a wide range of applications in the field of nano-medicine, particularly in drug delivery systems. The exclusive properties particularly small size and high surface area (which can be modified as required), exhibited by these nanoparticlesrender these structures more suitable for the purpose of drug delivery. Various nanostructures, like liposomes, dendrimers, mesoporous silica nanoparticles, etc. have been designed for the said purpose. These nanostructures have several advantages over traditional administration of medicine. Apart from overcoming the pharmacokinetic and pharmacodynamics limitations of many potential therapeutic molecules, they may also be useful for advanced drug delivery purposes like targeted drug delivery, controlled release, enhanced permeability and retention (EPR) effect. In this review, we attempt to describe an up-to-date knowledge on various strategically devised nanostructures to overcome the problems related to oral drug administration.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results